Clinical Trial Update: Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 pediatric MATCH trial evaluating palbociclib in relapsed or refractory pediatric tumors with activating alterations in cell cycle genes has completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Glioma
• Hepatoblastoma
• Medulloblastoma
• Neuroblastoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Wilms Tumor

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Status: COMPLETED | Results posted: 2024-04-24